This inventor holds 6 USPTO granted patents and 6 published patent applications. Top assignees: New York University, Wayne State University, The United States Government as Represented by the Department of Veterans Affairs. Active years: 2011-2026.
Location History:
- New York, NY (US) (2011 - 2016)
- Bronxville, NY (US) (2015 - 2017)
Company Filing History:
4 out of 1,726 
2 out of 602 
1 out of 955 
Years Active: 2011-2026
Title: Harvey I Pass: Innovator in Cancer Prognostics and Treatment
Introduction
Harvey I Pass is a notable inventor based in New York, NY (US), recognized for his contributions to the field of oncology. With a total of 6 patents, he has made significant strides in developing methods for diagnosing and treating non-small cell lung cancer (NSCLC). His innovative approaches have the potential to improve patient outcomes and enhance treatment strategies.
Latest Patents
One of his latest patents focuses on the "Use of circulating interleukin-18 for prognosticating and treating recurrence in early stage non-small cell lung cancer." This patent outlines methods for aiding in the diagnosis and treatment of NSCLC adenocarcinoma by determining elevated circulating Interleukin-18 (IL-18) values. The medical interventions based on these findings include additional scanning, surgical resection of tumors, and the administration of adjuvant therapies such as chemotherapy or immune therapy.
Another significant patent is the "System, method and computer-accessible medium for evaluating a malignancy status in at-risk populations and during patient treatment management." This innovative system, referred to as ImmunoRuler (IR), provides a visualization method for comparing groups of subjects with specific properties. It can be utilized to assess treatment efficacy and disease status among patients.
Career Highlights
Harvey I Pass has had a distinguished career, working with prestigious institutions such as New York University and Wayne State University. His work has been instrumental in advancing cancer research and treatment methodologies.
Collaborations
Throughout his career, he has collaborated with notable colleagues, including Anil Wali and Margaret E Huflejt. These partnerships have contributed to the development of his innovative patents and research initiatives.
Conclusion
Harvey I Pass stands out as a significant figure in the field of cancer research, with his patents paving the way for improved diagnostic and treatment options for non-small cell lung cancer. His contributions continue to impact the medical community and enhance patient care.